Next Generation Biologics: R&D, Industry and Market 2014-2024


Published on

For an Executive Summary of this report please contact (+44 (0)20 7549 9976) or refer to our website

Published in: Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Next Generation Biologics: R&D, Industry and Market 2014-2024

  1. 1. ©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision- gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur- chase and single copy is for personal use only. Next-Generation Biologics: R&D, Industry and Market 2014-2024
  2. 2. Next-Generation Biologics: R&D, Industry and Market 2014-2024 1.1 Next-Generation Biologics: World Market Review 2014 1.2 Report Contents 1.2.1 Benefits of this Report 1.3 Research and Analysis Methods 1.3.1 Financial Information in this Report 1.3.2 Who is this Report for? 1.4 An Introduction to Next-Generation Biologics 1.4.1 A Brief History of Biological Drug Development 1.4.2 Limitations to Current Generation Biologics 1.4.3 The Promise of Next-Generation Biologics Defining Next-Generation Biologics A Definition of Regenerative Medicine Extending Half-Life: Pegylation and Other Novel Strategies 2.1 The Next-Generation Biologics Market 2013 2.1.1 Development of the Next-Generation Biologics Market 2008-2013 2.1.2 Rising Demand for Biological Therapies 2.1.3 Next-Generation Drugs as a Share of the Biologics Market 2013 2.1.4 Main Sectors of the Next-Generation Biologics Market: Antibodies and Regenerative Medicine Lead the Way 2.1.5 Leading Companies in the Next-Generation Biologics Market 2013 2.2 The Next-Generation Biologics Market 2014-2024 2.2.1 The Biologics Market Forecast 2014-2024 Growth Drivers for Biological Drug Revenues 2014-2024 1. Executive Summary 2. The World Next-Generation Biologics Market: Outlook and Forecast 2014-2024
  3. 3. Next-Generation Biologics: R&D, Industry and Market 2014-2024 2.2.2 The Next-Generation Biologics Market Forecast 2014-2024 2.2.3 Product Launches in All Sectors to Drive Market Growth 2014-2024 2.2.4 Next-Generation Biologics: Market Restraints 2014-2024 2.2.5 Rising Market Shares for Next-Generation Insulins 2014-2024 3.1 Leading National Submarkets for Next-Generation Biologics 2013 3.1.1 National Submarket Forecasts 2014-2024 3.1.2 How Will National Submarket Shares Change to 2024? 3.2 Rising Disease Incidence in Major Markets 2014-2024 3.3 Approval of Next-Generation Biologics in Major National Submarkets 3.4 The US Will be the Largest Submarket for Next-Generation Biologics 2014-2024 3.4.1 US Submarket Forecast 2014-2024 3.5 Next-Generation Biologics in Japan 2014-2024 3.5.1. National Expertise in Stem Cell Research 3.5.2 Japanese Submarket Forecast 2014-2024 3.6 Next-Generation Biologics in Leading EU Nations 2014-2024 3.6.1 Regenerative Medicine Development in the EU 3.6.2 Market Access for Next-Generation Biologics in the EU 3.6.3 Germany: Submarket Forecast 2014-2024 3.6.4 France: Submarket Forecast 2014-2024 3.6.5 UK: Submarket Forecast 2014-2024 3.6.6 Italy and Spain: Submarket Forecasts 2014-2024 3.7 Next-Generation Biologics in Emerging Markets 2014-2024 3.7.1 Next-Generation Biologics Development in Emerging Markets 3.7.2 Chinese Submarket Forecast 2014-2024 3.7.3 Indian Submarket Forecast 2014-2024 3. Leading National Submarkets for Next-Generation Biologics 2014- 2024
  4. 4. Next-Generation Biologics: R&D, Industry and Market 2014-2024 4.1 Strategies for Improving Antibody Therapies 4.1.1 Antibody-Drug Conjugates: Targeted Cytotoxic Therapies 4.1.2 Engineering Antibodies for Improved Potency 4.1.3 Bispecific Antibodies 4.2 Next-Generation Antibody Therapy Submarket 2012-2013 4.3 Next-Generation Antibody Therapy Submarket 2014-2024 4.3.1 Strong Revenue Growth for Next-Generation Antibodies 2014-2024 4.3.2 Blockbuster Potential Will Drive Growth to 2024 4.3.3 Next-Generation Antibodies: Submarket Restraints 2014-2024 4.4 Antibody-Drug Conjugates Submarket 2014-2024 4.4.1 Antibody-Drug Conjugates Submarket Forecast 2014-2024 Kadcyla and Adcetris: Revenue Forecast 2014-2024 4.4.2 What Will Drive Growth for ADCs to 2024? 4.4.3 A Long Pipeline of ADCs in Clinical Development CMC544: NHL Development Halted but Trials in ALL Continue CDX-011: Potential for Accelerated Approval in Breast Cancer 4.5 Engineered Antibodies Submarket 2014-2024 4.5.1 Engineered Antibodies Submarket Forecast 2014-2024 Gazyva Will Lead the Submarket in 2024 4.5.2 Portfolio Management to Drive Growth 2014-2024 4.5.3 Engineered Antibodies Pipeline 2014 Benralizumab (MedImmune/Kyowa Hakko Kirin) 4.6 Bispecific Antibodies Submarket 2014-2024 4.6.1 Bispecific Antibodies Submarket Forecast 2014-2024 4.6.2 Bispecific Antibodies: Submarket Drivers and Restraints 2014-2024 4.6.3 One Phase III and Two Phase II Bispecific Antibodies in 2014 Blinatumomab (Amgen): The Only Phase III Bispecific Antibody 4. Next-Generation Antibodies Submarket Outlook 2014-2024
  5. 5. Next-Generation Biologics: R&D, Industry and Market 2014-2024 5.1 Next-Generation Antibody Fragments: Beyond Fab Fragments 5.1.1 Antibody-Like Proteins Mimic Antibody Therapies 5.1.2 There Are Advantages to Using Fragments and Novel Scaffolds 5.2 Antibody Fragment and ALP Submarket 2014-2024 5.2.1 Antibody Fragment and ALP Submarket Forecast 2014-2024 5.2.2 Pharma Is Investing Strongly in Antibody Fragments and ALPs 5.2.3 Limited Late-Stage Pipeline to Restrain Growth to 2024 5.3 Outlook for Next-Generation Antibody Fragments 2014-2024 5.3.1 Next-Generation Antibody Fragment Submarket Forecast 2014-2024 5.3.2 One Platform Leads the Pipeline in 2014 Three Nanobodies in Development for Rheumatoid Arthritis Caplacizumab (Ablynx): Targeting an Orphan Indication 5.4 The Antibody-Like Protein Submarket 2014-2024 5.4.1 Antibody-Like Protein Submarket Forecast 2014-2024 5.4.2 Four ALPs in Clinical Development in 2014 AGN-150998: Development of the Lead Clinical ALP Delayed 5.5 Will Next-Generation Immunotoxins Impact the Market to 2024? 5.5.1 Challenges with First Generation Immunotoxins 5.5.2 Fusion Protein Conjugates: Pipeline 2014 Moxetumomab Pasudotox 5.5.3 Humanised Immunotoxins Using Granzyme B in Immunotoxins Immunornases: A Future Development Opportunity for Immunotoxins 5. Antibody Fragments and Novel Antibody-Like Drugs: Commercial Potential 2014-2024
  6. 6. Next-Generation Biologics: R&D, Industry and Market 2014-2024 6.1 Strategies for Next-Generation Insulin Development 6.1.1 Reformulating Insulin for Convenient Administration Oral Insulin Inhaled Insulin Exubera: A Failed Attempt at Reformulated Insulin 6.2 Next-Generation Insulin Submarket 2012-2013 6.2.1 Tresiba: Approved in the EU and Japan Tresiba: Revenue Forecast 2014-2024 6.3 Next-Generation Insulin Submarket 2014-2024 6.3.1 Next-Generation Insulin Submarket Forecast 2014-2024 6.3.2 Product Launches in the US and EU Will Drive Submarket Growth 2014-2024 6.3.3 Next-Generation Insulin Submarket Restraints 2014-2024 Biosimilar Insulins Will be Available from 2015 6.4 Oral Insulin Submarket 2014-2024 6.4.1 Oral Insulin Submarket Forecast 2014-2024 6.4.2 Oral Insulin: Submarket Drivers and Restraints 2014-2024 6.4.3 A Limited Clinical-Stage Pipeline for Oral Insulin 2014 Oramed Pharmaceuticals: Oral Insulin in Phase II Novo Nordisk IN-105: Biocon Partners with Bristol-Myers Squibb for Development Diabetology: Multiple Deals Signed for Emerging Markets 6.5 Ultra-Rapid Acting Insulin Submarket 2014-2024 6.5.1 Ultra-Rapid Acting Insulin Submarket Forecast 2014-2024 Will Inhaled Insulins Drive Revenue Growth to 2024? 6.5.2 Other Submarket Drivers and Restraints 2014-2024 6.5.3 Ultra-Rapid Acting Insulin Pipeline 2014 FIAsp (Novo Nordisk) 6. Next-Generation Insulin Submarket: Outlook 2014-2024
  7. 7. Next-Generation Biologics: R&D, Industry and Market 2014-2024 Adocia: Eli Lilly Opts to Discontinue Partnership Halozyme Therapeutics Biodel: Multiple Ultra Rapid Acting Candidates Afrezza: Inhaled Insulin Nearing the Market Adagio: A Second-Generation Inhaled Insulin 6.6 Ultra-Long Acting Insulin Submarket 2014-2024 6.6.1 Ultra-Long Acting Insulin Submarket Forecast 2014-2024 6.6.2 Revenue Growth Driven by Uptake of Tresiba 6.6.3 Ultra-Long Acting Insulin Pipeline 2014 U300: Sanofi’s Next-Generation Insulin Analogue LY2605541 (Eli Lilly) FT-105 (Flamel Technologies) LAPS-Insulin 7.1 Defining Next-Generation for Other Recombinant Protein Sectors 7.1.1 Next-Generation Interferon Beta: Plegridy Set for Approval in 2014 Plegridy: Revenue Forecast 2014-2024 Plegridy May Compete with Other Long-Acting Interferon Beta Therapies 2014- 2024 7.1.2 Next-Generation G-CSF: Teva Expands its Filgrastim Franchise Other Clinical-Stages Advances in Filgrastim Therapy 2014 7.2 Next-Generation Recombinant Coagulation Factors 2014-2024 7.2.1 Next-Generation Recombinant Coagulation Factors Submarket Forecast 2014-2024 7.2.2 Submarket Drivers and Restraints 2014-2024 7.2.3 Clinical Pipeline for Recombinant Coagulation Factors 2014-2024 BAX 855 (Baxter) BAY94-9027 (Bayer) 7. Next-Generation Developments for Other Recombinant Proteins 2014-2024
  8. 8. Next-Generation Biologics: R&D, Industry and Market 2014-2024 N8-GP for Haemophilia A N9-GP for Haemophilia B Fused Factors: Biogen Idec’s Eloctate and Alprolix rIX-FP (CSL Behring): Albumin-Bound Coagulation Factors 7.2.4 Gene Therapy as a New Treatment Option for Haemophilia 7.3 Next-Generation Growth Hormones 2014-2024 7.3.1 Next-Generation Growth Hormone Submarket Forecast 2014-2024 7.3.2 Brand Loyalty Will Restrain Uptake of Next-Generation Hormones 2014-2024 7.3.3 Long-Acting Growth Hormones Biopartners/LG Life Sciences: The First Long-Acting Growth Hormone Prolor Biotech/OPKO Health Novo Nordisk: Looking to Extend its Market-Leading Position Versartis: XTEN Technology for Half-Life Extension 7.3.4 Reformulated Growth Hormones: Offering Convenient Dosing for Paediatric Patients Critical Pharmaceuticals: Nasal Delivery of Somatropin 8.1 The Regenerative Medicine Submarket 2012-2013 8.1.1 Defining Regenerative Medicine 8.2 The Regenerative Medicine Submarket: Revenue Projections 2014-2024 8.2.1 Stem Cell and Gene Therapy Launches to Drive Growth 2014-2024 8.3 The Stem Cell Therapies Submarket 2014-2024 8.3.1 Prochymal (Mesoblast) for GvHD The Future for Prochymal: Approval in Crohn’s Disease? 8.3.2 A Note on Stem Cell Transplants 8.3.3 Stem Cell Therapies Submarket Forecast 2014-2024 8.3.4 Stem Cell Therapies: Submarket Drivers and Restraints 2014-2024 Will iPSCs Prove Effective for Stem Cell Therapy? 8.3.5 Stem Cell Therapies Late-Stage Pipeline 2014 8. Regenerative Medicine: Commercial Outlook 2014-2024
  9. 9. Next-Generation Biologics: R&D, Industry and Market 2014-2024 Cx601 (TiGenix) Mesoblast: Mesenchymal Stem Cell Therapies Baxter Pharmaceuticals: A Leading Cardiovascular Candidate StemEx (Gamida Cell) 8.4 The Gene Therapies Submarket 2014-2024 8.4.1 Glybera Approved and Set for Launch in the EU 8.4.2 Gene Therapies Submarket: Revenue Projections 2014-2024 8.4.3 Glybera’s Approval to Drive Submarket Growth from 2014 8.4.4 There Are More Than Five Gene Therapies in Late-Stage Development ProstAtak: Gene Therapy for Prostate Cancer TVEC (Amgen) Generx (Cardium Therapeutics) Spark Therapeutics: Established in 2013 for Ophthalmic Gene Therapy 8.5 Outlook for Tissue Engineering 2014-2024 8.5.1 Two Sectors Lead the Market: Wound and Cartilage Repair Apligraf Leads the Wound Repair Submarket Organogenesis Will Market Apligraf and Dermagraft from 2014 8.5.2 Tissue Engineering Submarket Forecast 2014-2024 8.5.3 Tissue Engineering: Submarket Drivers and Restraints 2014-2024 8.5.4 Future Developments in Cartilage Repair: Pipeline 2014 8.5.5 Organ Repair and Engineering: The Next Step in Tissue Engineering? Engineered Skin Engineered Veins Organ Transplant: A Long-Term Tissue Engineering Opportunity 9.1 Next-Generation Biologics: Market Strengths 2014 9.2 Next-Generation Biologics: Market Weaknesses 2014 9.3 The Next-Generation Biologics Market: STEP Analysis 2014-2024 9. Next-Generation Biologics: Industry Trends 2014-2024
  10. 10. Next-Generation Biologics: R&D, Industry and Market 2014-2024 9.3.1 Social Factors: Rising Disease Incidence and Demands for Convenience Rising Incidence in Cancer, Diabetes and Cardiovascular Disease Next-Generation Biologic Development in Emerging Markets 9.3.2 Technological Developments 2014-2024 9.3.3 Economic Pressures 2014-2024 High Drug Costs and Healthcare Spending Limited Commercial Potential in Emerging Markets? 9.3.4 Political Issues: Regulatory Developments 2014-2024 9.4 Next-Generation Biologics: Development Trends 2014-2024 9.4.1 Improving Patient Convenience 9.4.2 Sustained Release Biologics: Pegylation and Beyond 9.4.3 Therapeutic Focus for Next-Generation Biologics 9.4.4 Next-Generation Biologics as Personalised Medicine 9.5 Manufacturing Challenges and Opportunities for Next-Generation Biologics 9.5.1 Contract Manufacturers Invest to Follow Development Trends 9.6 Commercialising Next-Generation Biologics 9.6.1 Product Lifecycle Management for First Generation Biologics 9.6.2 Proving Benefit in Next-Generation Products 9.6.3 Biosimilars as a Challenger 2014-2024 9.7 Partnering for Next-Generation Biologic Development 9.7.1 The Role of Big Pharma in the Next-Generation Biologics Market 9.7.2 Most Development Platforms Stem from Small Biotechs 10.1 Dr Fredrik Frejd, CSO, Affibody 10.1.1 Affibody 10.1.2 Challenges with Current Biological Therapies Current Half-Life Extension Technologies 10.1.3 The Benefits of Affibodies Over Current Antibody Therapies 10. Research Interviews from Our Survey
  11. 11. Next-Generation Biologics: R&D, Industry and Market 2014-2024 10.1.4 Focus on Inflammation and Autoimmune Diseases 10.1.5 Development of SOBI002 10.1.6 Regulatory Challenges for Novel Biologics 10.2 Dr Mike Romanos, CEO, Crescendo Biologics 10.2.1 Crescendo Biologics 10.2.2 The Benefits in Antibody Fragment Therapies 10.2.3 Treatment of Inflammation Indications with Antibody Fragments 10.2.4 Crescendo’s Fragment Pipeline 10.2.5 Development and Production Platforms for Antibody Therapies 11.1 The Next-Generation Biologics Market Will Grow Strongly to 2024 11.2 Next-Generation Antibody Development Will Lead the Market 11.3 New Treatment Regimens Will Drive Demand for Next-Generation Biologics 11.4 Challenges Remain in Developing and Commercialising Next-Generation Biologics About Visiongain’s Bespoke Research Service Appendix A: About Visiongain Appendix B: Visiongain Report Evaluation Form 11. Conclusions to Our Study Appendices
  12. 12. Page Next-Generation Biologics: R&D, Industry and Market 2014-2024 4.6.2 Bispecific Antibodies: Submarket Drivers and Restraints 2014- 2024 Table 4.17 identifies the main drivers and restraints that will impact the bispecific antibodies sector between 2014 and 2024. Market drivers stem from the large number of technology platforms available for bispecific development and the interest that these have attracted from Big Pharma companies. Some developers have been able to attract potential billion-dollar deals with pharmaceutical partners, with up-front fees in excess of $100m. This demonstrates a confidence in the technology from the pharmaceutical industry. In the second half of the period 2014-2024, submarket growth will be driven by the launch of new bispecific antibodies, starting with Amgen’s blinatumomab. That drug is targeting a multibillion dollar market sector - ALL - and could achieve revenues in excess of $0.50bn, we believe. A steady stream of approvals from 2018 onwards will drive strong growth in the bispecifics submarket. Although most of the advanced clinical programmes are targeting cancer indications, clinical trials and pre-clinical studies have demonstrated that bispecific antibodies hold potential outside that therapeutic sector. Restraints in the bispecific antibodies submarket stem from the limited late-stage pipeline and low revenues for currently approved products. In 2014 and 2015, the submarket will grow steadily as a result of no new product launches and continued low revenue for the one approved bispecific, Removab. While the number of platforms validated in pre-clinical studies indicates that there is huge promise for the bispecific antibodies sector, the fact that few have been validated in clinical studies means that the field is not yet reaching its potential, we believe. 2013 2014 2015 2016 2017 2018 Submarket Size ($bn) 0.00 0.00 0.00 0.06 0.07 0.19 Annual Growth (%) -2 8 1434 15 152 CAGR (%, 2013-2018) 116.0 2019 2020 2021 2022 2023 2024 Submarket Size ($bn) 0.34 0.55 0.74 0.90 1.06 1.23 Annual Growth (%) 81 63 33 23 17 16 CAGR (%, 2018-2024) 36.8 Source: visiongain 2014 Table 4.16 Bispecific Antibodies Submarket Forecast ($bn), 2013-2024
  13. 13. Page Next-Generation Biologics: R&D, Industry and Market 2014-2024 4.6.3 One Phase III and Two Phase II Bispecific Antibodies in 2014 In 2014, visiongain believes that the clinical pipeline for bispecific antibodies is shorter for than other leading sectors of the next-generation antibodies submarket. Despite multiple platforms being validated pre-clinically, there are just 16 clinical-stage projects, two thirds of which stem from three production platforms. Amgen’s BiTE platform accounts for five bispecific antibodies in clinical trials. The company gained ownership of the platform through its acquisition of Micromet in January 2012. BiTEs are bispecific T cell engagers manufactured by fusing single chain variable fragments from an anti-CD3 antibody to single chain variable fragments from other antibodies. In this respect, BiTE antibodies are similar to the antibody fragment molecules discussed in the next chapter. The most advanced candidate to come from the BiTE platform is blinatumomab, the only phase III candidate in the bispecific antibodies submarket in 2014 (Table 4.18). We believe that MacroGenics’ DART (dual-affinity re-targeting) platform is the second highest- profile bispecific antibody platform. MacroGenics reports that it has generated more than 100 bispecifics through its DART platform to date. The platform produces bispecific antibodies through the conjugation of two Fv fragments through a covalent linker. The resulting molecules have high stability, decreased immunogenicity and can be produced in microbial and mammalian cell cultures. Although no DART-based bispecifics have yet reached clinical trials, visiongain believes this is among the most promising platforms in the sector. MacroGenics has also developed an Fc optimisation platform, which can improve the binding affinity of antibodies. If this can be used in Drivers Restraints Bispecifics overcome specificity problems found with traditional monoclonal antibodies Manufacturing and stability are concerns for current bispecifics There is already one product available on the market There is only one product in phase III trials that will launch before the middle of the forecast period Leading bispecific platforms have attracted interest from Big Pharma companies Revenues for the one approved product remain low in 2014 There are many platforms with candidates in pre- clinical development Bispecific antibodies have potential uses outside of cancer Source: visiongain 2014 Table 4.17 Bispecific Antibodies Submarket: Drivers and Restraints, 2014-2024